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Relationship between Long-term Changea in Left
Ventricular Function and Clinical Outcome in
Patienta with Chronic Heart Failure Treated with
Carvedllol
M, Packer, W.S. Colucci, J.N. Cohn, MR. Sristow, M.B. Fowler,
E.M. Gilbert, J-Z Hu, N.H. Shusterman for the US Carvedilol Heart Failure
Study Group. Co/urrrbiaUrriverai~ New York,NY USA
Previoua studies have shown that carvedilol (CRV) can increasa LV ejec-
tion fraction (EF) and improve clinical outcome in patients with chronic heart
failure (CHF). We examined if there was a relationship between the hemo-
dynamic and clinical effects of the drug in 912 patients (NYHA II-IV, EF
s 0.35) who were enrolled in the US CarvediIol Program who had pre-
and post-treatment EF measurements. Cawedilol (CRV) or placebo (PBO)
were added for 8-12 months to conventional therapy with diuretics and ACE
inhibitor which remained constant. The proportion of pts who experienced
clinical deterioration (’?4.worse) and who were hospitalized for worsening
hearl failure (% heap) were compared in subsets with different EF responses
during treatment:
Carvedilol (n = 593) Placebo (n= 319)
A EF n 0/0worse “Ahosp n ‘h worse “hhosp
1 .,5 units 19 1s.1% 15.0% 33 2.9% 12.5%~ . . .
–5 to +5 249 7.3% 5.6”A 205 6,9”/0 11.3”/6
t >5 units 325 2,3% 3.1% 81 7.2% 8.5%
Not only was the propoflion of pts with EF T >5 greater with CRV than
PBO(P < 0.001), but patients whose EFTwith CRVhadalowerrisk of clinical
deterioration and hospitalization than patiants whoae EF was unchanged or
& No relationship betwean change in EF and clinical outcome was seen in
patients treated with PBO.
In conclusion, the clinical benefits of cawedilol in heart failure are closely
related to and thus may in part be mediated by the drug’s beneficial effects
on LVfunction.
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n7103 Hemodynamic Changes in Patients Undergoing Left
Ventricular Diameter Reduction (Batista Operation)
f.J.Take?,hita,A,T, Kawaguchi 1, P.R.N. Lima, L, Bocchino, J.L. Verde,
J.V.R. Batista. Hospital Angelina Caron, Curitiba, Brazil, I National
Cardiovascular Centec Osaka, Japan
To elucidate geometric-hemodynamic effects of surgical left ventricular (LV)
diameter reduction, 24patients underwent a paired angiographic-hemodynamic
studies 6 + 9 days before (PRE, n = 24) and 9 + 6 days (lMM, n = 20) or
136 + 95 days after the Batista operation (ERY, n = 5). Preoperatively all
patienta had advanced functional class (NYHA) due to underlying patholo-
gies including cardiomyopathy (15), valvular disease (6), ischemic disease
(2) and Chagas’ disease (l). The operation required 37 + 20 min of bypass,
ranging from 11to 90 min depending on associated procedures; aortic valve
replacement (4), mitral valve repair (10), tricuapid annuloplasty (10), coro-
nary bypass grafting (2) and auto-transplanation (l). After surgery the LV
end-systolic volume (ESV, ml) was reduced more than the end-diastolic vol-
ume (EDV, ml), reaulting in an increaaed stroke volume (SV,ml) and ejection
fraction (EF, %) without changes in heart rate (HR, bpm) and an elevated
filling pressure (EDP, mmHg), which appearad to come down with time after
surgery (ERY).
EDV ESV SV EF EDP HR CO NYHA
PRE 322 269 53 17.4 25.0 89 4.55 3.7
IMM 203 142 61 31.0 24,2 92 5.48 2.6
ERY 178 129 50 30.5 19,4 78 3.78 2.2
PRE4MM P<o.ol <0.01 <0.05 <0,01 NS NS <0,01 <0,01
PRWERY P<O.05 <0.05 NS <0.05 NS NS NS <0.05
The results suggest that the Batista operation reversed heart failure by
reducing both the syatolic and diastolic LV volumes in selected patients
immediately and early after surgery.
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Preliminary Obeervationa with Ventricular
Remodeling Surgery for Refractory Congestive
Heah Failure
R.C, Starling, J.B. Young, G.M. Scalia, J.D. Thomaa, R.L. Vargo, T.M. Buda,
N.G. Smadlra, P.M.McCarthy. The C/ave/and C//nic Fourrcfafiorr,C/eve/snd,
Ohjo, USA
The left ventricular remodeling procedure (LVR) was pioneered in Brazil and
touted to yield dramatic clinical and hemodynamic improvement in patients
(pts) with congestive heart failure (CHF). We believed that patients with LV
end diastolic diameter (LVIDd) >7.0 cm, dilated cardiomyopathy (DCM) and
NYHA 2-4 CHF awaiting heari transplant would improve if the LVIDd could
successfully be reduced. Seventeen patients, 11 M/6 F, mean age 50 + 10.8
years have undergone LVR with O% operative mortality and O% mortality
to date at 3; months follow-up. Fourteen patienta have been discharged
and three remain hospitalized. ICU length of stay (LOS) is 3.2 + 4 days and
hospital LOS is 10.7+ 3.4days. Hemodynamic and functional measurements
were made pre-operatively (PRE) and immediately post-operatively (POST).
LV ejection fraction (LV EF), volume (LVEDV) ml, LVIDd cm, stroke volume
(SV) ml, cardiac index l/m2 (Cl), and left atrial prassure mmHg (LA) were
measured.
N =15 LVEF LVEDV LVIDd Sv c1 LA
PRE 0.1510.07 2371s1 8.011.1 3219 2.010.6 24112
POST 0.3710.11 11s157 5.910.6 3919 2.610.6 1314
PValue <0,0001 <0,0001 <0,0001 0.03 0.013 0.0061
These prelimina~ results document marked hemodynamic and functional
improvement immediately post-op. Short-term clinical follow-up ia encourag-
ing, LVR may delay or supplant the need for heart transplantation in carefully
selected patients.
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m7105 Mechanism of Increased Mortality From Vesnsrinone
in the Severe Heart Failure Trial (VesT)
A. Feldman, J. Young, R. Bourge, P.Carson, B. Jaski, D. DeMets,
B,G. White, J.N. Cohn for the VesT Investigators. Pittsburgh, PA, USA,
Minneapolis, MN, USA
The Veanarinone (V) Trial (VesT) was a multi-center mortality study in 3,833
patients with Class III-IV heart failure. The patient population averaged 63
years old; ”76% were male, 84% white, 59% had a coronary artery disease
etiology and baseline ejection fraction averaged 217.. Background therapy
included ACE inhibitors in 90% of patients. Randomization was to placebo,
30 mgV or 60 mgV, an inotropic/K+ channel blocking drug. The trial was
terminated after the study-designed end-point of 232 placebo deaths had
occurred. V produced a dose-dependent increase in annual mortality rate
(AMR):
n Daatha AMR
Placebo 1283 239 23.5
30 mg 1275 266 26.5
60 mg 1275 2S9 29.1*
(“p < 0.02)
Adjudication of deaths was carried out by a central Morbidity/Mortality
Committee. The excess mottality in the 60 mg dose could be attributed to an
increase in sudden cardiac death rate. Non-mortality secondary end-points
(quality of life, hospitalization, worsening heart failure, adverse evants)
exhibited no sustained benefit of V.Therefore, despite a previous trial (NEJM
1993; 329: 149-155) demonstrating a favorable effect on mortality, a 60
mg daily dose of V was associated with no overall clinical banefit and en
increased risk of sudden death.
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1710+1cOmW~isOnOfT~eatmentpanernsand~utcOmes
Hesrt Fadure Pat#entswith Systolic Versus Diaatolic
Left Ventricular Dysfunction
F,A.McAlister, K.K. Tee, M. Taher, L. Cheung, M. Kiaii, R. Yim,
P.W.Armstrong, T.J. Montague, D.P.Humeri. University of A/berfa,
Edmonton, Albaria, Canada
Previous studies on patients with congestive heart failure (CHF) due to
systolic (SD) compared to those with diastolic left ventricular dysfunction
(DD) have been limited bv small samDle sizes, inclusion of hospitalized
&tients alone or exclusio~ of females. In thia study, data on 566 CHF
